Genelux (GNLX) Interest Coverage Ratio (2022 - 2023)
Genelux (GNLX) recorded quarterly Interest Coverage Ratio of 1166.83 in Q4 2023, down 823.44% quarter-over-quarter from 126.36 in Q3 2023, and down 10874.42% on a YoY basis from N/an in Q4 2022.
Genelux (GNLX) Interest Coverage Ratio (2022 - 2023) Analysis & Trends
Genelux's Interest Coverage Ratio history runs 2 years deep, the most recent figure standing at 1166.83 for Q4 2023.
- In Q4 2023, Interest Coverage Ratio fell 10874.42% year-over-year to 1166.83; the TTM figure through Sep 2024 stood at 4824.83 (down 82473.29% YoY), while the FY2023 annual figure was 139.68, down 5231.38% from the prior year.
- Interest Coverage Ratio was 1166.83 for Q4 2023 at Genelux, down from 126.36 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 22.18 in Q3 2022 to a low of 1166.83 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -1,166.83 |
| Sep 30, 2023 | -126.36 |
| Jun 30, 2023 | -224.79 |
| Mar 31, 2023 | -2.08 |
| Dec 31, 2022 | -10.63 |
| Sep 30, 2022 | 22.18 |